Last reviewed · How we verify
KB2115
At a glance
| Generic name | KB2115 |
|---|---|
| Sponsor | Karo Bio AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care (PHASE3)
- LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe (PHASE2)
- LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin (PHASE2)
- Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KB2115 CI brief — competitive landscape report
- KB2115 updates RSS · CI watch RSS
- Karo Bio AB portfolio CI